Lemborexant was discovered by Eisai Co. Ltd. in-house scientists. It is a novel investigational small molecule inhibiting orexin signaling by binding competitively to both orexin receptors subtypes (receptor 1 and 2). In January 2019, Eisai Co. Ltd. and Purdue Pharma L.P. submitted a new drug application (NDA) to the United States Food and Drug Administration (USFDA) for sleep-wake regulation.
Download the sample report at: https://www.pharmaproff.com/request-sample/1160
Both the companies are actively seeking drug’s approval for the treatment of insomnia. In addition, lemborexant is also being tested in the Phase II stage of clinical study, assessing patients with irregular sleep-wake rhythm disorder and mild to moderate Alzheimer’s dementia.
Get the detailed analysis at: https://www.pharmaproff.com/report/lemborexant
The report will include comprehensive insights about Lemborexant’s market launch. It will further include clinical trial analysis; strategic development details, such as collaborations, licensing, drug designations, and patent details. This report will also provide comprehensive insights upon how Lemborexant will evolve in the market as well as within its respective therapeutic class.
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]